Odevixibat (formerly known as A-4250; AZD-8294; A-4250; AR-H 064974; Bylvay) is a novel, potent and orally bioavailable inhibitor of ileal bile acid transporter (IBAT) with the potential to be used for the treatment of primary biliary cirrhosis. As of July 2021, Odevixibat has been approved in the United States and in the European Union for the treatment of progressive familial intrahepatic cholestasis (PFIC).

纯度：≥98%

CAS：501692-44-0